EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Get Free Report) has been given an average recommendation of “Buy” by the ten analysts that are currently covering the company, Marketbeat reports. Ten ...

(RTTNews) - EyePoint Pharmaceuticals, Inc. (EYPT), Wednesday announced positive six-month results from the ongoing Phase 2 VERONA clinical trial, evaluating Duravyu for the treatment of diabetic ...

Shares of EyePoint Pharmaceuticals (NASDAQ:EYPT) rose 10% Wednesday after the company reported positive six-month results from a phase 2 study of its drug Duravyu in the treatment of diabetic macular ...

EyePoint Pharmaceuticals, Inc. (EYPT) is up by 3.66 percent during Monday trading, rising $0.28 to $7.90. The stock moved higher ...

Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ: NASDAQ:EYPT) tumbled 21% following the release of positive clinical trial results for their DURAVYU™ treatment, confounding analysts who viewed the ...

EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections ...

EyePoint Pharmaceuticals, Inc. ( NASDAQ:EYPT ) shareholders should be happy to see the share price up 16% in the ...

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Get Free Report) saw a large increase in short interest in the month of January.As of January 15th, there was short interest totalling 10,340,000 ...

Citi has initiated coverage of EyePoint Pharmaceuticals (NASDAQ:EYPT) with a buy rating, stating it sees the company's drug Duravyu as well-positioned to compete in the wet age-related macular ...

WATERTOWN, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...